Events in 2023
CONGRESS 2023 - Do we (k)need a hip new approach? Experience of an international trial of the Biofire Joint Infection Panel
28/09/2023
This presentation will give delegates a:
Real world evaluation of a syndromic panel compared to traditional Gram stain and culture
The presentation will cover:
An outline of the trial
A summary of findings
The local experience of the process
Brief local case studies that show how the multiplex PCR panel results could have positively affected patient management.
Real world evaluation of a syndromic panel compared to traditional Gram stain and culture
The presentation will cover:
An outline of the trial
A summary of findings
The local experience of the process
Brief local case studies that show how the multiplex PCR panel results could have positively affected patient management.
CONGRESS 2023 - Dimorphine-assisted treatment programme
28/09/2023
Dimorphine-assisted treatment programme
CONGRESS 2023 - Point-of-Care Testing in the community
28/09/2023
To introduce a discovery community Point of Care Testing project that is working collaboratively with primary and secondary care.
By working in wider partnerships, the project aims are to scope and work towards recommendations and collaboration to deliver effective and measurable benefits for safer patient care and a governance led service, aligned to national NHS strategy plans.
By working in wider partnerships, the project aims are to scope and work towards recommendations and collaboration to deliver effective and measurable benefits for safer patient care and a governance led service, aligned to national NHS strategy plans.
CONGRESS 2023 - Pets to pandemics – viral zoonoses
28/09/2023
It is clear that the interaction of humans with animals and the environment has been at the centre of infectious disease emergence and spread through out history. Recent global events have shown that this is still the case, or at least likely to be! Close contact with animals and our collective movements in and out of each others environments has the potential to permit transmission of organisms that have the potential to cause zoonotic or indeed enzoonotic disease. We need to consider this aspect carefully to understand what mitigations we might need to put into place and also what considerations might need to be taken on board in the light of changes to infection patterns as a possible consequence of climate change.
CONGRESS 2023 - A quality culture - supporting daily quality and compliance
28/09/2023
Delegates will understand:
What is a quality culture.
Importance of obtaining and maintaining ISO accreditation.
Maintaining and improving quality and compliance.
Key tips for supporting daily quality and compliance.
What is a quality culture.
Importance of obtaining and maintaining ISO accreditation.
Maintaining and improving quality and compliance.
Key tips for supporting daily quality and compliance.
CONGRESS 2023 - Pandemics – Past (polio; smallpox; Ebola)
28/09/2023
This lecture will overview previous viral pandemics affecting humans and highlight lessons learned (or not). This lecture will provide the audience with background information relevant to the two subsequent talks on pandemics currently affecting and what might come next. At the end of this talk the audience will have knowledge on some major pathogenic viruses that have impacted hugely on the human population including:
Smallpox; influenza; polio; yellow fever; HIV and Ebola that bring us up to the novel coronavirus outbreaks that have plagued mankind during more recent years.
Smallpox; influenza; polio; yellow fever; HIV and Ebola that bring us up to the novel coronavirus outbreaks that have plagued mankind during more recent years.
CONGRESS 2023 - Biomarkers, disease severity and triaging the role of mid-regional proadrenomodulin
28/09/2023
There is a lack of validated tools to assess potential disease progression and hospitalisation decisions in patients presenting to the emergency department (ED) with a suspected infection. The aim to identify suitable blood biomarkers (MR-proADM, PCT, lactate and CRP) and/ or clinical scores (SIRS, SOFA, qSOFA, NEWS and CRB-65) to fulfil this unmet clinical need and recognising the “ill looking well” and the “well looking ill”. We found in patients presenting to the ED with a suspected infection, the blood biomarker MR-proADM could most accurately identify the likelihood of further disease progression.
Incorporation into an early sepsis management protocol may therefore aid rapid decision-making in order to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment. There is currently a randomised controlled trial to assess the accuracy of the above findings.
Incorporation into an early sepsis management protocol may therefore aid rapid decision-making in order to either initiate, escalate or intensify early treatment strategies, or identify patients suitable for safe out-patient treatment. There is currently a randomised controlled trial to assess the accuracy of the above findings.
CONGRESS 2023 - Crossroads to a Compatible Career: From Pipette to Patient Blood Management
28/09/2023
Crossroads to a Compatible Career: From Pipette to Patient Blood Management
CONGRESS 2023 - Future: Preparedness planning & what might come next
28/09/2023
Future: Preparedness planning & what might come next
Page 23 of 31